Investor Relations (IR) Questions: Antares Pharma ATRS
Click here to return to the biotech IRQ Index
Visit the BiotechDueDiligence Antares Pharma ATRS stock research page for more info on this company
Answers received: February 2013
The following are notes from my telephone conversation with Antares Pharma's VP of Corporate Affairs, Jack Howarth.
1) When is the last time ATRS raised cash through an offering (diluted)?
The company's last offering was in October 2012. The company sold 12.5 million shares at $4.00 a share. Net proceeds to the company were $46.7 million.
2) How much cash (not cash equivalents) does ATRS have?
The company last reported cash for the 3rd quarter of 2012. At the time northward of $30 million was reported (this included equivalents and short term investments). Since that time the company also generated $46.7 million from an offering.
The company has not said when it will release fourth quarter results for 2012. In years past it has been the week of March 11th however a date has not been set yet.
3) What and approximately when is the next known catalyst?
The next catalyst will be some notification from the FDA regarding the submission of a NDA for Otrexup last December. They're expecting to hear something at any time now.
For additional catalysts, Jack recommended that I reference the company's slide at the close of the company's posted presentation that puts a list together of what is expected in the next 12 to 18 months.
If you are not familiar with ATRS's pipeline I recommend taking a closer look. This company has allot going on and many of their programs are in advanced stages. Here is a link: http://www.antarespharma.com/pipeline/.
ATRS is also partnered with a number of big name companies like Pfizer, TEVA and Watson.
4) What is ATRS's quarterly cash burn?
Last year it was around a $1.5 million per quarter. No guidance has been given for this year. However, the company has said that it would go up in 2013 based on the programs being worked on.
5) Does ATRS have an existing line of credit and if so how much can they draw against it?
Jack said that he was not aware of the company having a credit line.
Answers received: February 2013
The following are notes from my telephone conversation with Antares Pharma's VP of Corporate Affairs, Jack Howarth.
1) When is the last time ATRS raised cash through an offering (diluted)?
The company's last offering was in October 2012. The company sold 12.5 million shares at $4.00 a share. Net proceeds to the company were $46.7 million.
2) How much cash (not cash equivalents) does ATRS have?
The company last reported cash for the 3rd quarter of 2012. At the time northward of $30 million was reported (this included equivalents and short term investments). Since that time the company also generated $46.7 million from an offering.
The company has not said when it will release fourth quarter results for 2012. In years past it has been the week of March 11th however a date has not been set yet.
3) What and approximately when is the next known catalyst?
The next catalyst will be some notification from the FDA regarding the submission of a NDA for Otrexup last December. They're expecting to hear something at any time now.
For additional catalysts, Jack recommended that I reference the company's slide at the close of the company's posted presentation that puts a list together of what is expected in the next 12 to 18 months.
If you are not familiar with ATRS's pipeline I recommend taking a closer look. This company has allot going on and many of their programs are in advanced stages. Here is a link: http://www.antarespharma.com/pipeline/.
ATRS is also partnered with a number of big name companies like Pfizer, TEVA and Watson.
4) What is ATRS's quarterly cash burn?
Last year it was around a $1.5 million per quarter. No guidance has been given for this year. However, the company has said that it would go up in 2013 based on the programs being worked on.
5) Does ATRS have an existing line of credit and if so how much can they draw against it?
Jack said that he was not aware of the company having a credit line.